Stocks and Investing
Stocks and Investing
Thu, August 6, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Jonathan Chang Maintained (ADAP) at Hold with Decreased Target to $10 on, Aug 6th, 2020
Jonathan Chang of SVB Leerink, Maintained "Adaptimmune Therapeutics plc" (ADAP) at Hold with Decreased Target from $11 to $10 on, Aug 6th, 2020.
Jonathan has made no other calls on ADAP in the last 4 months.
There are 2 other peers that have a rating on ADAP. Out of the 2 peers that are also analyzing ADAP, 1 agrees with Jonathan's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Mara Goldstein of "Mizuho" Maintained at Hold with Increased Target to $9 on, Monday, June 1st, 2020
This is the rating of the analyst that currently disagrees with Jonathan
- Mohit Bansal of "Citigroup" Maintained at Strong Buy with Decreased Target to $5 on, Monday, April 27th, 2020